The approval was based on data from 5 randomized, double-blind, placebo-controlled trials that included 317 patients with supraventricular tachycardia.

AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...

Vaccination of 'mid-adults,' including those at higher risk, results in higher number needed to vaccinate than that seen for younger people ...

There was an increase in quarterly prescription rates from 4.2% in July to September 2021 to 23.5% in July to September 2023. (HealthDay News) — From 2021 to 2023, there was an increase in ...

STS101 is an investigational DHE nasal powder product administered through a proprietary nasal delivery device.

According to Soleno Therapeutics, the FDA required more time to review responses to recent information requests.